Speech-Language Pathologists in Hiawatha, KS Accepting Medicare

10 Speech-Language Pathologists found. Showing 1 - 10

Kindra Howard, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 210 S. 4th Street, Hiawatha, KS 66434 Phone: 785-742-6464    Fax: 785-742-6592

Mr. Bryan S Potter Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Oregon St, Hiawatha, KS 66434 Phone: 785-742-2464    Fax: 785-742-2552

Kaitlin Mccullough, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 210 S. 4th Street, Hiawatha, KS 66434 Phone: 785-742-6464    Fax: 785-742-6592

June Marie Gerety, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 201 S 4th St., Hiawatha, KS 66434 Phone: 785-742-6464

Mrs. Melissa J Gilliland Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Oregon St, Hiawatha, KS 66434 Phone: 785-742-2464    Fax: 785-742-2552

Mr. Rick A Morrison Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Oregon St, Hiawatha, KS 66434 Phone: 785-742-2462    Fax: 785-742-2552

Ms. Jena Michelle Meyer, M.A., CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 201 S 4th St, Hiawatha, KS 66434 Phone: 785-742-6464

Morrison, Potter, & Associates, Inc Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 201 S 4th St, Hiawatha, KS 66434 Phone: 785-742-2464    Fax: 785-742-2552

Mrs. Mandy R Graham Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 600 Oregon St, Hiawatha, KS 66434 Phone: 785-742-2464    Fax: 785-742-2552

Karen L Ross, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 600 Oregon St, Hiawatha, KS 66434 Phone: 785-742-2464    Fax: 785-742-2552

News Archive

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

Cardiome total revenue for fiscal 2010 is $66.1 million

Cardiome Pharma Corp. today reported financial results for the fourth quarter and year ended December 31, 2010.

Envision Conference 2014 kicks off with presentation of two prestigious awards

Envision announced today that Second Sight Medical Products, Inc., a San Fernando Valley, Calif.-based medical device manufacturer, and Janet Sunness, M.D., Medical Director of Richard E. Hoover Low Vision Rehabilitation Services at Greater Baltimore Medical Center in Towson, Md., were named the 2014 recipients, respectively, of the Envision Oculus Award and Envision Award in Low Vision Research, two prestigious honors acknowledging substantial contributions to furthering research and facilitating collaborative efforts toward addressing low vision and the conditions that cause it.

Researchers have identified the cellular receptor for the JC virus

Researchers funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the cellular receptor for the JC virus, which causes the fatal neurological disease progressive multifocal leukoencephalopathy (PML).

Astute Medical, Fosun Long-March sign distribution agreement for NephroCheck Test on the Astute140 Meter

Astute Medical, Inc. today announced the signing of an agreement with Shanghai Fosun Long March Medicine Science Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co. Ltd., for distribution of Astute's NephroCheck Test on the Astute140 Meter in China. In addition to its planned launch of the NephroCheck Test in China, FOSUNPHARMA invested $20 million in Astute.

Read more Medical News

› Verified 7 days ago